Musculoskeletal pain: evidence varies by indication · Review · 2023
Which kinds of muscle and joint pain may shockwave help?
In this review, results depended on the problem and the comparison. In one trial, outer hip pain eased more with shockwave than with a steroid injection after a year; in another, athletes with groin pain returned to football sooner. Studies of low-back function and carpal tunnel syndrome showed little difference.
- studies included
- 98
- people in the outer-hip trial (shockwave vs steroid injection)
- 104
- athletes in the groin-pain study
- 44
Good to know: A broad overview of 98 studies across many conditions, selected by the authors.
De la Corte-Rodríguez H, Román-Belmonte JM, Rodríguez-Damiani BA, et al. Healthcare (Basel), 2023 · Read the paper ↗
How this study worked
Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.
Who took part
People with tendon problems, heel pain, back pain, knee arthritis, bone-healing and blood-vessel problems, and carpal tunnel syndrome, across many studies.
Side effects
Bruising is more likely at higher strengths, and treatment can be uncomfortable. One Achilles tendon tear two weeks after a session is reported; it is unclear whether shockwave caused it.
All the numbers and the full appraisal
Every reported result
What the full paper reports.
Multiple tendon disorders, plantar fasciitis, axial pain, knee osteoarthritis, bone healing and vascular disorders, and carpal tunnel syndrome. Participants recur across cited reviews; there is no independent aggregate patient count.
Selected comparative findings1 reported outcome
Selected comparative findings
Qualitative finding
Selected examples: a 104-person trochanteric trial reported 12-month VAS 37.1 versus 55.0 after injection comparison; a 44-athlete pubic-pain study reported return to football at 73.2 versus 102.6 days. Important null findings include low-back function, short-term patellar placebo comparisons, knee function versus PRP and carpal-tunnel comparisons with steroid injection. No common effect or certainty estimate can be derived.
Analysis details and source
Qualitative extraction preserves the source scope.
Benefits that did not persist1 reported outcome
Benefits that did not persist
Qualitative finding
Ten-person coccydynia study improved at four weeks and two months but not seven months; carpal-tunnel add-on review found only transient four-week benefit. A 34-person coccydynia series reported VAS 9.6±0.5 to 3±3.2 at six months without a control.
Analysis details and source
Qualitative extraction preserves the source scope.
Harms reporting1 reported outcome
Harms reporting
Qualitative finding
Bruising is associated with higher intensity; treatment discomfort and a reported Achilles rupture two weeks after a session are discussed, with causality uncertain. No pooled adverse-event denominator is supplied. Absence of significant events in many reports is not a measured zero-risk rate.
Analysis details and source
Qualitative extraction preserves the source scope.
How treatment was delivered
Bruising is associated with higher intensity; treatment discomfort and a reported Achilles rupture two weeks after a session are discussed, with causality uncertain. No pooled adverse-event denominator is supplied. Absence of significant events in many reports is not a measured zero-risk rate.
Subjective selection and heterogeneous controls limit conclusions. Table 3 lists nine 1− entries although the abstract says eight; avascular hip necrosis and femoral-head osteonecrosis overlap conceptually. Grades are not an outcome-specific GRADE assessment. Reference 79 is the historical Ogden overview, not a modern pooled trial analysis. No external funding or conflicts declared.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Subjective selection and heterogeneous controls limit conclusions. Table 3 lists nine 1− entries although the abstract says eight; avascular hip necrosis and femoral-head osteonecrosis overlap conceptually. Grades are not an outcome-specific GRADE assessment. Reference 79 is the historical Ogden overview, not a modern pooled trial analysis. No external funding or conflicts declared.
Source-linked critical reading
clinical synthesis
Technical source record
Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. External supplements not supplied with the intake were not read.
The usefulness of shockwaves depends on the diagnosis and comparison treatment. Some studies show benefit, others show little difference; this review does not give one success rate for everyone.
Which musculoskeletal pain conditions have supporting evidence for ESWT, and how consistent are protocols?
Narrative review searching five databases on 11 August 2023. It reports 3,517 records, 149 screened, 115 considered relevant and 98 included, prioritizing higher-level studies. The stated exclusion count of 34 does not explain the transition from 115 to 98. No new pooled analysis was performed.
Multiple tendon disorders, plantar fasciitis, axial pain, knee osteoarthritis, bone healing and vascular disorders, and carpal tunnel syndrome. Participants recur across cited reviews; there is no independent aggregate patient count.
Focused and radial modalities are distinguished. Table 2 gives condition-specific session and pulse ranges, but the authors acknowledge no consensus. General dosing statements and table recommendations differ; these are review suggestions, not a validated universal prescription.
Placebo, exercises, physical modalities, injections and surgery vary by indication. Shared rehabilitation and differences between radial and focused treatment complicate cross-study comparisons.
Pain and function dominate, with return to sport, imaging, union and electrophysiology in specific indications. Follow-up ranges from weeks to years; imaging improvement need not track symptom improvement.
Selected examples: a 104-person trochanteric trial reported 12-month VAS 37.1 versus 55.0 after injection comparison; a 44-athlete pubic-pain study reported return to football at 73.2 versus 102.6 days. Important null findings include low-back function, short-term patellar placebo comparisons, knee function versus PRP and carpal-tunnel comparisons with steroid injection. No common effect or certainty estimate can be derived.
Bruising is associated with higher intensity; treatment discomfort and a reported Achilles rupture two weeks after a session are discussed, with causality uncertain. No pooled adverse-event denominator is supplied. Absence of significant events in many reports is not a measured zero-risk rate.
Subjective selection and heterogeneous controls limit conclusions. Table 3 lists nine 1− entries although the abstract says eight; avascular hip necrosis and femoral-head osteonecrosis overlap conceptually. Grades are not an outcome-specific GRADE assessment. Reference 79 is the historical Ogden overview, not a modern pooled trial analysis. No external funding or conflicts declared.
An orientation map for clinicians, requiring indication-specific appraisal. Broad claims of safety and efficacy should not replace the null and uncertain findings described in the body.
Conduct transparent condition-specific systematic reviews, reconcile selection counts, separate modalities and co-interventions, and use blinded trials with prespecified function, pain, harms and durable follow-up.
Read the original article.
Extracorporeal Shock Wave Therapy for the Treatment of Musculoskeletal Pain: A Narrative Review
De la Corte-Rodríguez H, Román-Belmonte JM, Rodríguez-Damiani BA, Vázquez-Sasot A, Rodríguez-Merchán EC. · Healthcare (Basel) · 2023
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →